Drugs Approved for Myeloproliferative Disorders

This page lists cancer drugs approved by the Food and Drug Administration (FDA) for myeloproliferative disorders. The list includes generic and brand names. This page also lists common drug combinations used in myeloproliferative disorders. The individual drugs in the combinations are FDA-approved. However, drug combinations themselves usually are not approved, but are widely used.

The drug names link to NCI's Cancer Drug Information summaries. There may be drugs used in myeloproliferative disorders that are not listed here.

Adriamycin PFS (Doxorubicin Hydrochloride)
Adriamycin RDF (Doxorubicin Hydrochloride)
Arsenic Trioxide
Azacitidine
Cerubidine (Daunorubicin Hydrochloride)
Clafen (Cyclophosphamide)
Cyclophosphamide
Cytarabine
Cytosar-U (Cytarabine)
Cytarabine
Cytoxan (Cyclophosphamide)
Dacogen (Decitabine)
Dasatinib
Daunorubicin Hydrochloride
Decitabine
Doxorubicin Hydrochloride
Gleevec (Imatinib Mesylate)
Imatinib Mesylate
Jakafi (Ruxolitinib Phosphate)
Lenalidomide
Mylosar (Azacitidine)
Neosar (Cyclophosphamide)
Nilotinib
Revlimid (Lenalidomide)
Rubidomycin (Daunorubicin Hydrochloride)
Ruxolitinib Phosphate
Sprycel (Dasatinib)
Tarabine PFS (Cytarabine)
Tasigna (Nilotinib)
Trisenox (Arsenic Trioxide)
Vidaza (Azacitidine)
Vincasar PFS (Vincristine Sulfate)
Vincristine Sulfate
 

Drug Combinations Used in Myeloproliferative Disorders

ADE
 

Back to Top